Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 150
interventional 138
Observational 9
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 91
Drug|placebo 6
Device 5
Drug|Other 5
Biological 4
Drug|Procedure 4
Other 4
Procedure 4
Biological|Drug 3
Behavioral 2
Drug|Other|Procedure 2
Drug|Radiation 2
Behavioral|Other 1
Combination Product 1
Device|Procedure 1
Dietary Supplement 1
Drug|Other|Procedure|Radiation 1
Other|placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 33
Korea, Republic of 22
China 20
Japan 12
United Kingdom 6
Taiwan 5
France 4
Italy 4
NA 4
Germany 3
Austria 2
Canada 2
Denmark 2
Norway 2
Belgium 1
Korea, Republic of|Singapore|Taiwan 1
Saudi Arabia 1
Spain 1
Sweden 1
Switzerland 1
United States|Argentina|Australia|Austria|Belgium|Czechia|Denmark|France|Germany|Hungary|Japan|Korea, Republic of|Mexico|Russian Federation|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Chile|Japan|Korea, Republic of|Poland|Spain|Taiwan 1
United States|Argentina|Bulgaria|Chile|China|France|Hong Kong|India|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Australia|Canada|Chile|France|Germany|Israel|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Canada|Czechia|Germany|Hungary|Italy|Korea, Republic of|Russian Federation|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|China|Hong Kong|Hungary|Japan|Korea, Republic of|Poland|Singapore|Spain|Taiwan 1
United States|Belgium|United Kingdom 1
United States|China|France|Italy|Japan|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|France|Germany|Japan|Spain|United Kingdom 1
United States|France|Spain 1
United States|Taiwan 1

Sites per Study

Site_count Study_Count
1 84
2 12
3 8
4 4
5 4
6 3
7 5
9 1
10 1
11 1
14 1
15 1
16 1
17 2
21 1
22 1
32 1
46 1
48 1
68 1
73 1
92 1
148 1
620 1

Phase

Phase Study_Count
Phase 2 77
Phase 1 16
N/A 13
Phase 1/Phase 2 13
Phase 3 11
Phase 2/Phase 3 4
Phase 4 4

Number of Arms

Number_of_Arms Count_of_Studies
1 67
2 54
3 5
4 3
6 1
8 1
9 1
NA 6

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 20.0000 6.00 20.0000 4.00000 124.0 162.0000 43.00
1st Qu. 99.0000 16.00 40.0000 31.00000 254.5 274.5000 54.25
Median 140.0000 24.00 68.0000 45.00000 394.0 308.0000 59.00
Mean 142.3077 43.75 105.6923 66.66234 356.0 396.3636 140.25
3rd Qu. 200.0000 48.25 85.0000 70.00000 495.5 425.0000 145.00
Max. 288.0000 155.00 362.0000 600.00000 512.0 828.0000 400.00

Trial Group Type

group_type Group_Count
Experimental 182
Active Comparator 29
Placebo Comparator 8
NA 6
No Intervention 4
Other 2

Intervention Model

intervention_model Study_Count
Single Group Assignment 76
Parallel Assignment 54
Sequential Assignment 6
NA 2

Primary Purpose

primary_purpose Study_Count
Treatment 127
Supportive Care 7
Diagnostic 3
Other 1

Observational Studies

Studies by Country

Country Study_Count
China 2
Japan 2
United States 2
Italy 1
Korea, Republic of 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 7
4 1
9 1

Enrollment Metrics

Measure Observational
Min 30.0000
1st Qu 100.0000
Median 113.0000
Mean 495.6667
3rd Qu 300.0000
Max 2624.0000

Observation Model

observational_model Study_Count
Cohort 4
Case-Only 3
Case-Control 2

Time Perspective

time_perspective Study_Count
Prospective 7
Retrospective 2

Registries

Studies by Country

Country Study_Count
United States 2
Korea, Republic of 1

Sites per Study

Site_count Study_Count
1 2
5 1

Enrollment Metrics

Measure Registries
Min 100
1st Qu 550
Median 1000
Mean 970
3rd Qu 1405
Max 1810

Registry Model

observational_model Study_Count
Cohort 2
Case-Control 1

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
1 Year 1
3 Years 1
6 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03406299 Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03406299 Recruiting National Health Research Institutes, Taiwan 2020-06-30
NCT03358849 Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell (“SMT-NK”) Cell Therapy in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03358849 Completed Yonsei University 2018-09-27
NCT03314935 A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors https://ClinicalTrials.gov/show/NCT03314935 Recruiting Incyte Corporation 2021-10-06
NCT03291899 Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT03291899 Recruiting King Faisal Specialist Hospital & Research Center 2019-08-31
NCT03278106 TAS-102 in Treating Advanced Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT03278106 Active, not recruiting Mayo Clinic 2018-11-30
NCT03260712 Pembrolizumab in Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03260712 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2022-11-01
NCT03231176 Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03231176 Active, not recruiting Aslan Pharmaceuticals 2020-03-31
NCT03185988 Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System https://ClinicalTrials.gov/show/NCT03185988 Recruiting Peking University 2021-07-31
NCT03162510 Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers https://ClinicalTrials.gov/show/NCT03162510 Recruiting National Health Research Institutes, Taiwan 2021-12-31
NCT03111732 Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) https://ClinicalTrials.gov/show/NCT03111732 Recruiting National Institutes of Health Clinical Center (CC) 2020-12-31
NCT03110328 Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes https://ClinicalTrials.gov/show/NCT03110328 Recruiting Samsung Medical Center 2020-08-31
NCT03101566 Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03101566 Active, not recruiting University of Michigan Rogel Cancer Center 2019-12-03
NCT03093870 Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03093870 Active, not recruiting Aslan Pharmaceuticals 2019-07-31
NCT02293954 Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer https://ClinicalTrials.gov/show/NCT02293954 Active, not recruiting City of Hope Medical Center 2020-06-30
NCT03082053 A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours https://ClinicalTrials.gov/show/NCT03082053 Completed Aslan Pharmaceuticals 2017-12-07
NCT03079427 Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma https://ClinicalTrials.gov/show/NCT03079427 Recruiting Asan Medical Center 2021-04-30
NCT03044587 Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer https://ClinicalTrials.gov/show/NCT03044587 Recruiting AIO-Studien-gGmbH 2019-12-31
NCT02992340 Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC https://ClinicalTrials.gov/show/NCT02992340 Recruiting Aslan Pharmaceuticals 2020-06-30
NCT02988635 Early Palliative Care on Quality of Life of Advanced Cancer Patients https://ClinicalTrials.gov/show/NCT02988635 Completed Azienda Ospedaliero-Universitaria di Parma 2016-11-30
NCT02966821 Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma https://ClinicalTrials.gov/show/NCT02966821 Completed Hutchison Medipharma Limited 2018-08-17
NCT02943031 The Effect of Individualized Precision Therapy Programs in Patients With BTC https://ClinicalTrials.gov/show/NCT02943031 Recruiting RenJi Hospital 2020-12-31
NCT02908451 A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer https://ClinicalTrials.gov/show/NCT02908451 Recruiting AbGenomics B.V Taiwan Branch 2020-10-31
NCT02866383 Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients https://ClinicalTrials.gov/show/NCT02866383 Recruiting Herlev Hospital 2020-11-30
NCT02829918 Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT02829918 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2019-03-27
NCT02821754 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) https://ClinicalTrials.gov/show/NCT02821754 Recruiting National Institutes of Health Clinical Center (CC) 2020-12-31
NCT02773459 MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02773459 Completed Seoul National University Hospital 2019-01-07
NCT02711553 A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02711553 Active, not recruiting Eli Lilly and Company 2018-02-16
NCT02703714 Pembrolizumab and GM-CSF in Biliary Cancer https://ClinicalTrials.gov/show/NCT02703714 Active, not recruiting University of California, San Francisco 2020-05-31
NCT02670265 Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions https://ClinicalTrials.gov/show/NCT02670265 Completed University Medicine Greifswald 2014-02-28
NCT02632305 A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02632305 Recruiting AHS Cancer Control Alberta 2020-01-31
NCT02586987 A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours https://ClinicalTrials.gov/show/NCT02586987 Completed AstraZeneca 2018-07-25
NCT02443324 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02443324 Active, not recruiting Eli Lilly and Company 2018-08-31
NCT04298021 DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04298021 Recruiting Seoul National University Hospital 2021-03-31
NCT04298008 AZD6738 Plus Durvalumab in Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04298008 Recruiting Seoul National University Hospital 2021-03-31
NCT02558959 Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02558959 Completed Zhejiang University 2017-09-30
NCT01758341 Radiofrequency Ablation for Malignant Biliary Obstruction https://ClinicalTrials.gov/show/NCT01758341 Completed Medical University of Vienna 2013-05-31
NCT02489422 Programs To Support You During Chemotherapy https://ClinicalTrials.gov/show/NCT02489422 Completed Wake Forest University Health Sciences 2020-01-31
NCT02433639 Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02433639 Completed Seoul National University Hospital 2017-10-31
NCT02425137 A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02425137 Completed TTY Biopharm 2017-05-31
NCT02386397 Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02386397 Completed Institut du Cancer de Montpellier - Val d’Aurelle 2019-12-31
NCT02351765 ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT02351765 Completed The Christie NHS Foundation Trust 2019-03-31
NCT02350686 XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy https://ClinicalTrials.gov/show/NCT02350686 Recruiting Samsung Medical Center 2019-12-31
NCT02346032 Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma https://ClinicalTrials.gov/show/NCT02346032 Completed Samsung Medical Center 2016-09-30
NCT02182778 GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02182778 Completed Kansai Hepatobiliary Oncology Group 2016-02-04
NCT02146703 Gemcitabine and S-1 for Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02146703 Completed Hallym University Medical Center 2010-11-30
NCT02102984 Covered Versus Uncovered Biliary Stents for Biliary Malignancies https://ClinicalTrials.gov/show/NCT02102984 Completed Nuovo Ospedale Civile S.Agostino Estense 2015-09-30
NCT01315522 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents https://ClinicalTrials.gov/show/NCT01315522 Completed Seoul National University Hospital 2014-11-30
NCT01308840 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer https://ClinicalTrials.gov/show/NCT01308840 Completed University of Rochester 2013-01-31
NCT01297998 A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy https://ClinicalTrials.gov/show/NCT01297998 Completed Kansai Hepatobiliary Oncology Group 2012-12-31
NCT01291615 Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT01291615 Completed Kansai Hepatobiliary Oncology Group 2012-10-31
NCT01284413 Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT01284413 Completed Kansai Hepatobiliary Oncology Group 2012-08-31
NCT02002806 Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control https://ClinicalTrials.gov/show/NCT02002806 Completed Indiana University 2018-12-31
NCT01943864 A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT01943864 Completed GlaxoSmithKline 2014-07-01
NCT01926236 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT01926236 Completed The Christie NHS Foundation Trust 2018-01-05
NCT01853618 Tremelimumab With Chemoembolization or Ablation for Liver Cancer https://ClinicalTrials.gov/show/NCT01853618 Completed National Institutes of Health Clinical Center (CC) 2017-06-07
NCT01821248 A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis https://ClinicalTrials.gov/show/NCT01821248 Active, not recruiting Kansai Hepatobiliary Oncology Group 2016-09-27
NCT01815307 Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT01815307 Completed Kansai Hepatobiliary Oncology Group 2016-05-31
NCT01731821 Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy https://ClinicalTrials.gov/show/NCT01731821 Completed Fudan University 2014-06-30
NCT01713387 A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy https://ClinicalTrials.gov/show/NCT01713387 Completed Kansai Hepatobiliary Oncology Group 2015-04-30
NCT01661114 A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers https://ClinicalTrials.gov/show/NCT01661114 Completed University of Michigan Rogel Cancer Center 2014-12-31
NCT01595217 MRCP Diagnoses EHCC Better When Combined DWI https://ClinicalTrials.gov/show/NCT01595217 Completed China Medical University, China 2013-03-31
NCT01589328 Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB https://ClinicalTrials.gov/show/NCT01589328 Completed National Cancer Center, Korea 2017-06-30
NCT01572324 Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas https://ClinicalTrials.gov/show/NCT01572324 Completed Peking University 2015-10-31
NCT01530503 Second Line Therapy in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT01530503 Completed IRCCS San Raffaele 2013-10-31
NCT01375972 Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma https://ClinicalTrials.gov/show/NCT01375972 Completed Asan Medical Center 2011-07-31
NCT04333927 Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer https://ClinicalTrials.gov/show/NCT04333927 Active, not recruiting Sun Yat-sen University 2024-06-30
NCT04329429 A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer. https://ClinicalTrials.gov/show/NCT04329429 Recruiting RemeGen 2022-08-01
NCT04318834 Molecular Profiling of Advanced Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT04318834 Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre 2022-04-30
NCT04308174 Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04308174 Recruiting Asan Medical Center 2021-09-30
NCT04300959 Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04300959 Recruiting Zhejiang Cancer Hospital 2021-01-31
NCT04238637 Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) https://ClinicalTrials.gov/show/NCT04238637 Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 2023-12-31
NCT04234113 Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT04234113 Recruiting Sotio a.s. 2022-03-31
NCT04203160 Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) https://ClinicalTrials.gov/show/NCT04203160 Recruiting University of Michigan Rogel Cancer Center 2024-06-30
NCT04186156 A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04186156 Active, not recruiting Karus Therapeutics Limited 2023-03-31
NCT04172402 NGS as the First-line Treatment in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04172402 Recruiting National Health Research Institutes, Taiwan 2022-12-31
NCT04163900 Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04163900 Recruiting NuCana plc 2023-12-31
NCT04111380 Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT04111380 Recruiting Henan Provincial People’s Hospital 2023-03-31
NCT04072445 Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04072445 Recruiting Mayo Clinic 2021-05-15
NCT04057365 Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) https://ClinicalTrials.gov/show/NCT04057365 Recruiting Massachusetts General Hospital 2022-08-31
NCT04027764 Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT04027764 Recruiting Chinese PLA General Hospital 2020-05-01
NCT04005339 NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer https://ClinicalTrials.gov/show/NCT04005339 Recruiting Georgetown University 2021-07-31
NCT04004234 A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC https://ClinicalTrials.gov/show/NCT04004234 Recruiting Chinese PLA General Hospital 2020-08-31
NCT03943043 Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03943043 Recruiting Istituto Clinico Humanitas 2020-05-01
NCT03937895 Allogeneic NK Cell (“SMT-NK”) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03937895 Recruiting SMT bio Co., Ltd. 2021-02-02
NCT03875235 Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) https://ClinicalTrials.gov/show/NCT03875235 Recruiting AstraZeneca 2022-06-30
NCT03873532 A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients https://ClinicalTrials.gov/show/NCT03873532 Recruiting Hutchison Medipharma Limited 2021-06-30
NCT03833661 M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) https://ClinicalTrials.gov/show/NCT03833661 Active, not recruiting EMD Serono 2020-11-09
NCT03830606 The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma https://ClinicalTrials.gov/show/NCT03830606 Recruiting Chinese Academy of Medical Sciences 2019-03-02
NCT03801083 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT03801083 Recruiting University of Pittsburgh 2021-01-31
NCT03796429 A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03796429 Recruiting Shanghai Zhongshan Hospital 2022-12-01
NCT03790111 A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03790111 Recruiting Lexicon Pharmaceuticals 2020-12-31
NCT03785873 Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03785873 Recruiting University of Michigan Rogel Cancer Center 2023-05-31
NCT03779035 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection https://ClinicalTrials.gov/show/NCT03779035 Recruiting Tianjin Medical University Cancer Institute and Hospital 2020-12-31
NCT03768414 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT03768414 Recruiting Southwest Oncology Group 2024-01-01
NCT03673072 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC https://ClinicalTrials.gov/show/NCT03673072 Recruiting Krankenhaus Nordwest 2024-11-30
NCT03639935 Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy https://ClinicalTrials.gov/show/NCT03639935 Recruiting University of Michigan Rogel Cancer Center 2022-01-31
NCT03631173 Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy https://ClinicalTrials.gov/show/NCT03631173 Recruiting Oslo University Hospital 2020-06-01
NCT03613168 Trastuzumab in HER2-positive Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03613168 Recruiting Asan Medical Center 2020-09-01
NCT03531320 Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase https://ClinicalTrials.gov/show/NCT03531320 Recruiting InnoPharmax Inc. 2019-10-31
NCT03524508 Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03524508 Active, not recruiting Asan Medical Center 2020-08-31
NCT03482102 Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03482102 Recruiting Massachusetts General Hospital 2021-10-31
NCT03478488 Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC https://ClinicalTrials.gov/show/NCT03478488 Recruiting 3D Medicines (Sichuan) Co., Ltd. 2021-12-31
NCT03475953 A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors https://ClinicalTrials.gov/show/NCT03475953 Recruiting Institut Bergonié 2020-11-30
NCT03464968 mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line https://ClinicalTrials.gov/show/NCT03464968 Recruiting Seoul National University Bundang Hospital 2019-12-25
NCT03427242 Apatinib for Advanced Biliary Carcinoma https://ClinicalTrials.gov/show/NCT03427242 Recruiting Fudan University 2021-10-31
NCT03411200 Patient Activation Through Counseling, Exercise and Mobilization https://ClinicalTrials.gov/show/NCT03411200 Recruiting Herlev and Gentofte Hospital 2020-05-01
NCT01242605 ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT01242605 Completed University College, London 2013-03-31
NCT01216345 Cetuximab + Gemox in Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT01216345 Completed Association of Research on the Biology of Liver Tumors 2008-10-31
NCT01127555 Salvage mFOLFOX in BTC After Failure of Gemcitabine https://ClinicalTrials.gov/show/NCT01127555 Completed Chung-Ang University 2012-06-30
NCT00987766 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer https://ClinicalTrials.gov/show/NCT00987766 Completed Vanderbilt-Ingram Cancer Center 2013-07-31
NCT00980889 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction https://ClinicalTrials.gov/show/NCT00980889 Completed Stockholm South General Hospital 2012-06-30
NCT00939848 Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT00939848 Completed University College, London 2012-09-30
NCT04352023 Analgesic Efficacy After Pancreatobiliary Surgery: Intravenous Versus Patient-controlled Epidural https://ClinicalTrials.gov/show/NCT04352023 Active, not recruiting National Cancer Center, Korea 2020-04-30
NCT04066491 Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) https://ClinicalTrials.gov/show/NCT04066491 Recruiting EMD Serono 2022-11-24
NCT00832689 Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT00832689 Completed Yonsei University 2010-02-28
NCT01917617 Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT01917617 Completed Kansai Hepatobiliary Oncology Group 2016-01-07
NCT01825603 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT01825603 Completed University of Nebraska 2017-06-30
NCT03046862 Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT03046862 Recruiting Seoul National University Hospital 2020-05-31
NCT02579616 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy https://ClinicalTrials.gov/show/NCT02579616 Completed Eisai Inc. 2019-03-27
NCT02784353 Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy https://ClinicalTrials.gov/show/NCT02784353 Recruiting Asan Medical Center 2019-12-31
NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) https://ClinicalTrials.gov/show/NCT03797326 Active, not recruiting Merck Sharp & Dohme Corp. 2024-02-24
NCT00753675 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT00753675 Completed Sanofi 2012-09-30
NCT00747097 Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study https://ClinicalTrials.gov/show/NCT00747097 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2010-09-30
NCT00626158 Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers https://ClinicalTrials.gov/show/NCT00626158 Completed University of California, San Francisco 2010-12-31
NCT00553332 Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00553332 Completed National Cancer Institute (NCI) 2013-01-31
NCT00552149 Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin https://ClinicalTrials.gov/show/NCT00552149 Completed Gustave Roussy, Cancer Campus, Grand Paris 2012-04-30
NCT00423254 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. https://ClinicalTrials.gov/show/NCT00423254 Completed Mannkind Corporation 2009-09-30
NCT00422409 Endoscopic Stenting of Gastrointestinal Cancer https://ClinicalTrials.gov/show/NCT00422409 Completed Oslo University Hospital 2009-04-30
NCT00380588 Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT00380588 Completed Eli Lilly and Company 2008-10-31
NCT00363584 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT00363584 Completed National Cancer Institute (NCI) 2013-08-31
NCT00361231 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer https://ClinicalTrials.gov/show/NCT00361231 Completed Massachusetts General Hospital 2009-03-31
NCT00338988 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma https://ClinicalTrials.gov/show/NCT00338988 Completed M.D. Anderson Cancer Center 2009-05-31
NCT00268840 The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer https://ClinicalTrials.gov/show/NCT00268840 Completed ARCAGY/ GINECO GROUP 2006-02-28
NCT00196105 Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) https://ClinicalTrials.gov/show/NCT00196105 Completed Cook Group Incorporated 2006-12-31
NCT00174564 EXIBIT: Oxaliplatin in Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT00174564 Completed Sanofi 2006-09-30
NCT00142480 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer https://ClinicalTrials.gov/show/NCT00142480 Completed Massachusetts General Hospital 2007-07-31
NCT00123825 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT00123825 Completed Dana-Farber Cancer Institute 2007-10-31
NCT00073905 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT00073905 Completed Swiss Group for Clinical Cancer Research 2006-06-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02809898 The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02809898 Recruiting RenJi Hospital 2020-12-31
NCT01962168 Evolution® Biliary Stent System Clinical Study https://ClinicalTrials.gov/show/NCT01962168 Completed Cook Group Incorporated 2015-03-31
NCT01294085 Case Series Study of Biliary Tract Cancer Patients in Japan https://ClinicalTrials.gov/show/NCT01294085 Completed Kansai Hepatobiliary Oncology Group 2011-02-28
NCT01950572 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT01950572 Recruiting National Institutes of Health Clinical Center (CC) 2033-07-25
NCT01861483 Vessel Resection and Reconstruction of Biliary Tract Cancers https://ClinicalTrials.gov/show/NCT01861483 Completed Kansai Hepatobiliary Oncology Group 2014-03-31
NCT01657383 Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery https://ClinicalTrials.gov/show/NCT01657383 Completed Atrium Health 2016-12-31
NCT03718897 Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing https://ClinicalTrials.gov/show/NCT03718897 Recruiting Seoul National University Hospital 2020-09-02
NCT03668418 Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos https://ClinicalTrials.gov/show/NCT03668418 Recruiting University of Pisa 2021-05-31
NCT00339560 A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China https://ClinicalTrials.gov/show/NCT00339560 Completed National Institutes of Health Clinical Center (CC) 2008-05-21

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02917759 Liver and Biliary Tumor Tissue Registry https://ClinicalTrials.gov/show/NCT02917759 Recruiting Mayo Clinic 2024-02-29
NCT02908048 Extracellular RNA Markers of Liver Disease and Cancer https://ClinicalTrials.gov/show/NCT02908048 Active, not recruiting Mayo Clinic 2021-07-31
NCT03695952 A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors https://ClinicalTrials.gov/show/NCT03695952 Recruiting Asan Medical Center 2020-07-31